Jens Lamerz

Roche (Switzerland) — Switzerland

Medicine · Health Sciences

18h-index850citations44works3.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(12), Advanced Proteomics Techniques and Applications(9), Lung Cancer Research Studies(6), HER2/EGFR in Cancer Research(4), RNA modifications and cancer(4)

Publications44 total

<p>Enabling Oligonucleotide Oral Delivery: How Sodium Caprate Impact Tablet Manufacturability and Biopharmaceutical Performance</p>
SSRN Electronic Journal·2026Open Access
Development of a blending design space model to control blend uniformity in a mini-batch direct compression line
Powder Technology·2025· 3 cited
Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Male Mice
Biological Psychiatry Global Open Science·2024· 5 citedOpen Access
QbD Approach to Process Characterization and Quantitative Criticality Assessment of Process Parameters
Organic Process Research & Development·2024· 8 cited
Pharmacological Enhancement of Adult Hippocampal Neurogenesis Improves Behavioral Pattern Separation in Young and Aged Mice
2024· 1 citedOpen Access
Development of a Continuous Flow Grignard Reaction to Manufacture a Key Intermediate of Ipatasertib
Organic Process Research & Development·2023· 7 cited
Supplementary Figure 2 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Figure 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Figure 2 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Table 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Methods from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Table 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Figure 1 from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Data from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Supplementary Methods from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Data from Quantitative Chemical Proteomics Profiling Differentiates Erlotinib from Gefitinib in <i>EGFR</i> Wild-Type Non–Small Cell Lung Carcinoma Cell Lines
2023Open Access
Impact of non-ionizable lipids and phase mixing methods on structural properties of lipid nanoparticle formulations
International Journal of Pharmaceutics·2023· 30 citedOpen Access
An Improved Impact Ratio for Identifying Critical Process Parameters in Pharmaceutical Manufacturing Processes
PDA Journal of Pharmaceutical Science and Technology·2022· 4 cited
Symmetric signal transduction and negative allosteric modulation of heterodimeric mGlu1/5 receptors
Neuropharmacology·2020· 24 citedOpen Access
A Risk Index and Data Display for Process Performance in the Pharmaceutical Industry
PDA Journal of Pharmaceutical Science and Technology·2017
page 1 of 3Next →

Frequent Co-authors

Angélique Augustin(19), Sabrina Golling(18), Manuel Tzouros(17), Hélène Meistermann(16), Hanno Langen(16), Laurent Essioux(13), David Ávila(12), Barbara Klughammer(12), Stefan Scheiblich(11), Johannes C. Hermann(11), Guillemette Duchâteau-Nguyen(11), Paul Cutler(7), Hartmut Selle(5), Hans‐Dieter Zucht(5), Axel Ducret(4), Gonzalo Durán-Pacheco(3), Martin Ebeling(3), Arno Friedlein(3), Ravi Jagasia(3), Indira Mendez‐David(3)